Biotech - Big Pharma Collaborations: Modified And Terminated Agreements, Dec. 23, 2005-Feb. 22, 2006
I. MODIFIED AGREEMENTS | |||
Biotech Co.* | Pharma Co. | Change from original | Terms/Details (Date) |
AEterna | Solvay Pharmaceuticals BV (Belgium | AEterna regained rights to cetrorelix for benign prostate hyperplasia except in Japan; late-stage trials are planned | Solvay is continuing development of the LHRH antagonist in gynecological indications; no payment was made in the restructuring of the January 2004 deal (1/30) |
Biomira Inc. | Merck KGaA (Germany) | Merck will takes over administrative and financial responsibility for the liposome cancer vaccine L-BLP25 | Biomira's co-promotion interest in U.S. sales will be converted to a royalty structure; Biomira retains manufacturing rights, and rights in Canada; milestone terms remain the same (1/26) |
Celera | Abbott Laboratories | They restructured deal focused on development of molecular diagnostics | They will continue working together in most areas in a profit-sharing arrangement but can work individually in certain other areas (1/9) |
Cephalon Inc. | Barr Laboratories Inc. | They settled patent litigation related to Cephalon's Provigil and Actiq products | Barr got nonexclusive rights to market a generic version of Provigil in the U.S. starting in October 2011 and to market a generic version of Actiq starting in December 2006; Cephalon would get royalties (2/1) |
Cephalon Inc. | Mylan | They settled a patent | Mylan got a nonexclusive, royalty-bearing right to market a generic version of Provigil starting in October 2011 (1/10) |
Oscient | Vicuron Pharmaceuticals Inc. (unit of Pfizer Inc.) | Oscient, which had rights to Ramoplanin in the U.S. and Canada, acquired worldwide rights and assumed full control of the product | Pfizer gets an up-front payment and potential milestone and royalty payments; the drug is nearing Phase III trials for treating Clostridium difficile-associated disease (2/8) |
Progenics | UR Labs Inc. | Progenics acquired a substantial portion of the royalty and milestone rights to methylnaltrexone (MNTX) | Progenics initially licensed rights to the drug from UR Labs in 2001; UR Labs received 686,000 Progenics shares and $2.6M in cash (12/23) |
II. TERMINATED AGREEMENTS | |||
Enzon | Fresenius Biotech GmbH (division of Fresenius AG; Germany) | Enzon returned rights to ATG-Fresenius S, a polyclonal antibody preparation designed for suppressing T lymphocytes | Enzon licensed North American rights to the transplant rejection product in June 2003; Enzon said ending the deal was due to a redirected focus at the company (1/6) |
Epigenomics | Roche Diagnostics (Switzerland) | Roche is returning rights to a test for Tamoxifen treatment response and breast cancer molecular classification | Epigenomics plans to develop the test itself; they remain partnered on screening products for colon, prostate and breast cancers (1/30) |
Ligand | Organon USA Inc. | They terminated co-promotion deal covering the pain drug Avinza | Ligand regained rights to the product and will continue paying royalties to Organon; they also resolved a dispute concerning prior co-promotion fees (1/17) |
NeuroSearch | Boehringer Ingelheim GmbH (Germany) | BI terminated deal covering the development of tesofensine (NS2330) | The move followed unsuccessful Phase II trials in 2005 in Alzheimer's and Parkinson's diseases; NeuroSearch plans continued development with a new partner (1/25) |
NitroMed Inc. | Boston Scientific Corp. | A research program on nitric oxide-enhancing technology came to a close Dec. 31 | The technology was being studied with restenosis in balloon angioplasty; NitroMed intends to continue to explore using the technology in medical devices (12/29) |
Santarus Inc. | TAP Pharmaceutical Products Inc. | TAP exercised its right to terminate June 2002 sublicense agreement | TAP had North American rights to use Santarus' immediate- release proton pump inhibitor technology with lansoprazole, a PPI; Santarus now has worldwide rights to the technology (1/9) |
SciGen Ltd. | Ferring AG | Ferring is terminating deal under which it supplied human growth hormone in Singapore and South Korea | SciGen said it has taken measures to ensure it has adequate supplies for those markets; they are discussing continuation of the collaboration (2/3) |
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; PK = Pink Sheets. | |||